E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Infections Caused by Acinetobacter baumannii-calcoaceticus Complex |
|
E.1.1.1 | Medical condition in easily understood language |
Infections Caused by Acinetobacter baumannii-calcoaceticus Complex |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003999 |
E.1.2 | Term | Bacteremia |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10046577 |
E.1.2 | Term | Urinary tract infections |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037597 |
E.1.2 | Term | Pyelonephritis acute |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10076918 |
E.1.2 | Term | Hospital acquired pneumonia |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10065153 |
E.1.2 | Term | Ventilator associated pneumonia |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10078408 |
E.1.2 | Term | Surgical site infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To compare the efficacy of ETX2514SUL plus imipenem/cilastatin to colistin plus imipenem/cilastatin in patients with carbapenem-resistant ABC (CRABC) infections in Part A; •To compare the incidence of nephrotoxicity, as measured by the Risk–Injury–Failure–Loss–End stage renal disease (RIFLE) criteria, of ETX2514SUL to colistin in patients with ABC infections in Part A.
|
|
E.2.2 | Secondary objectives of the trial |
•To compare the efficacy of ETX2514SUL plus imipenem/cilastatin to colistin plus imipenem/cilastatin in all randomized patients in Part A; •To evaluate the efficacy of ETX2514SUL plus imipenem/cilastatin in patients with colistin resistant ABC infections in Part B; •To estimate the efficacy of ETX2514SUL plus imipenem/cilastatin for each primary infection site; •To evaluate and compare the safety of ETX2514SUL and colistin; •To describe the overall safety profile of ETX2514SUL; •To determine the systemic exposure of ETX2514 and sulbactam in a small cohort of severely ill patients administered ETX2514SUL in Part A. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
General Inclusion Criteria for Part A and B: 1. A signed informed consent form. If a study patient is unable to provide informed consent due to their medical condition, the patient’s legally authorized representative may consent on behalf of the study patient, as permitted by local law and institutional Standard Operating Procedures; 2. Male or female 18 years of age or older; 3. A confirmed diagnosis of a serious infection and the expectation, in the judgment of the Investigator, that the patient’s infection will require treatment with intravenous (IV) antibiotics; 4. A known infection caused by ABC (bacteremia, HABP, VABP, complicated urinary tract infection [cUTI] or acute pyelonephritis [AP], or surgical or post traumatic wound infections) as either a single pathogen or member of a polymicrobial infection based on evidence from culture or, if available, rapid diagnostic test from a sample collected within 72 hours prior to randomization (HABP/VABP patients), AND 1 of the following: a. Has received no more than 48 hours of effective empiric therapy prior to enrollment; OR b. Is clinically failing prior treatment regimens (ie, clinical deterioration or failure to improve after at least 48 hours of antibiotic treatment); Note: Rapid testing of respiratory specimens utilizing Biofire® FilmArray® 2.0 Pneumonia Panel (BPP) technology may be used to enable early identification of ABC pneumonia. Patients can be randomized based on the results of the BPP rapid test while awaiting results of cultures from the local laboratory. However, if the respiratory sample does not grow ABC in the local microbiology laboratory culture, these patients will be withdrawn from the study drug treatment. 5. Expectation, in the judgment of the Investigator, that the patient will survive at least 72 hours with effective antibiotic therapy and appropriate supportive care for the anticipated duration of the study; 6. Women of childbearing potential (ie, not post-menopausal or surgically sterilized) must have a negative serum pregnancy test before randomization. Participating women of childbearing potential must be willing to consistently use 2 highly effective methods of contraception (ie, condom, combined oral contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized partner) from Screening until at least 30 days after administration of the last dose of study drug; and 7. Male participants must be willing to use condoms during sexual intercourse from Screening until at least 90 days after administration of the last dose of study drug. |
|
E.4 | Principal exclusion criteria |
1. Presence of suspected or confirmed deep-seated infection, including lung abscess in patients with pneumonia, that is not planned on being drained within 24 hours after randomization; 2. Evidence of active concurrent community-acquired pneumonia caused by e.g. Streptococcus pneumoniae, Haemophilus influenzae, etc; 3. Presence of suspected or confirmed osteomyelitis, endocarditis, or meningitis, as determined by history and/or physical examination; 4. Irremovable implantable device or line thought to be the potential source of infection; 5. Sustained shock with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) higher or equal to 60 mmHg AND having a serum lactate >2 mmol/L (18 mg/dL) despite adequate volume resuscitation; 6. For patients to be enrolled with the primary indication of HABP or VABP, any of the following conditions: a. Diagnosis of ventilator-associated tracheobronchitis; or b. Inability to provide proper respiratory specimens for culture. Respiratory samples from expectorated or induced sputum should show <10 squamous epithelial cells and >25 polymorphonuclear neutrophils per 100 field; 7. For patients to be enrolled with the primary indication of cUTI or AP, any of the following urologic conditions: a. Likely to receive ongoing antibacterial drug prophylaxis after treatment of cUTI (eg, patients with vesico-uretal reflux); b. Suspected or confirmed prostatitis; c. Requirement for bladder irrigation with antibiotics or for antibiotics to be administered directly via urinary catheter; d. Previous or planned cystectomy or ileal loop surgery; e. Uncomplicated urinary tract infection (eg, female patients with urinary frequency, urgency, or pain or discomfort without systemic symptoms or signs of infection); f. Complete, permanent obstruction of the urinary tract; g. Suspected or confirmed perinephric or renal corticomedullary abscess; h. Polycystic kidney disease; or i. Any recent history of trauma to the pelvis or urinary tract; 8. Moribund patients or patients with evidence of immediately life-threatening disease where, in the opinion of the Investigator, the patient is unlikely to survive more than 72 hours after Day 1; 9. Pregnant or breastfeeding women; 10. APACHE II score >30 at the time of diagnosis of infection; 11. Receiving chronic hemodialysis or peritoneal dialysis; 12. Known seizure disorder requiring current treatment with antiseizure medication that, in the opinion of the Investigator, would prohibit the patient from complying with the protocol. 13. Requirement for continuing treatment with probenecid, methotrexate, ganciclovir, valproic acid, or divalproex sodium during the study; 14. Evidence of significant hepatic disease or dysfunction, 15. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 upper limit of normal (ULN) AND total bilirubin >2 ULN at Screening; 16. Requirement at the time of randomization for any reason, or likely to require during the patient’s participation in the study (from randomization through the Late Follow-up [LFU] Visit), for additional systemic antimicrobial therapy (including Gram negative antibacterial, antiviral, antimycobacterial, or antifungal therapy) other than study drug, with the exception of a single oral dose of any antifungal treatment for vaginal candidiasis; 17. Requirement for inhaled antibiotics; 18. Known history of human immunodeficiency virus infection and known recent CD4 count <200/mm3 within the last year or presence of significant immunologic disease or dysfunction; 19. Presence of neutropenia (absolute neutrophil count <500/mm3) obtained from a local laboratory at Screening; 20. A QT interval corrected using Fridericia’s formula higher or equal to 80 msec; 21. History of significant hypersensitivity or allergic reaction to any β-lactam (BL), any contraindication to the use of cilastatin based on local approved prescribing information, any contraindication to the excipients used in the respective formulations, or any contraindication to the use of BL antibiotics; 22. Participation in a clinical study within the last 30 days or 5 half-lives, whichever is longer, prior to Day 1; 23. Any condition that would compromise the safety of the patient or the quality of the data or require greater than 14 days of treatment with antibiotics; 24. Unable or unwilling to comply with the protocol; 25. Has previously received study drug in this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
28-day all-cause mortality in the CRABC m-MITT Population in Part A. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 5, Day 7, EOT, TOC, and LFU Visits. |
|
E.5.2 | Secondary end point(s) |
•28-day all-cause mortality in the ITT Population; •Attributable mortality in the CRABC m-MITT Population, if, at the discretion of the Investigator, the death is related to the indication infection (ie, ABC); •Clinical cure at TOC in the CRABC m-MITT Population; •Clinical cure at TOC in the m-MITT, Clinical Evaluable (CE), Microbiologic Evaluable (ME), and CRABC ME Populations; •Clinical cure at Day 5, Day 7, EOT, and LFU in the m-MITT, CRABC m MITT, CE, ME, and CRABC ME Populations; •Microbiological favorable assessment at Day 5, Day 7, EOT, TOC, and LFU in the m-MITT, CRABC m-MITT, ME, and CRABC ME Populations; •14-day all-cause mortality in the CRABC m-MITT and m-MITT Populations; •28-day all-cause mortality in the m-MITT and CRABC ME Populations; and •PK exposure of ETX2514 and sulbactam in the PK Population. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Part A: Assessor and Sponsor blinded; Part B: open-label non randomised |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belarus |
Brazil |
China |
Greece |
Hungary |
India |
Israel |
Italy |
Korea, Democratic People's Republic of |
Lithuania |
Mexico |
Peru |
Russian Federation |
Spain |
Taiwan |
Thailand |
Turkey |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of Study in this study is defined as the last visit or last study-related contact (whichever comes last) of the last patient worldwide.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |